Redeye provides a research update following the Q3 report recently published by Coegin Pharma. While the report itself did not include any significant surprises, the company manages to continue operating on a low cash burn. However, the quarter was primarily marked by the company’s TO3 warrants period. As the company has successfully raised some much-needed capital, we see enticing potential in the stock.